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An exemplar population-based study to predict up-take of non-intensive therapies in acute myeloid
leukaemia
1. Introduction
Recent advances in non-intensive therapy (non-IC) have demon-
strated the potential for improved outcomes in patients with non-pro-
myelocytic acute myeloid leukaemia (AML) unsuitable for intensive
chemotherapy [1]. These data are mainly derived from clinical trial
participants and therefore numbers of unselected patients that could
benefit from novel agents are unknown. Identifying factors that influ-
ence treatment decisions in unselected patients would be useful to
predict up-take of non-IC. A previous study on Medicare beneficiaries
has identified variables influencing intensive treatment in older AML
patients, but not the reasons for favouring SC over non-IC [2]. As the
use of non-IC in patients increases [3], predicting the size of the target
population for non-IC, identifying barriers to therapy and the de-
terminants of survival in ‘real-world’ patients will help budgetary
planning and patient outcomes. In the absence of a national registry of
AML patients in the United Kingdom, through this retrospective study,
we aimed to identify the proportion of AML patients that receives non-
IC in our catchment population of 450,000, and factors affecting
treatment and survival.
2. Methods
2.1. Study design and patient cohort
Following National Health Service (NHS) Caldicott Guardian ap-
proval, patients diagnosed with AML from 2001 to 2018 were identified
from the data archives of the immunophenotyping laboratory. All pa-
tients were diagnosed and managed by haematologists based in NHS
Tayside teaching hospitals. Medical and laboratory records were used
to abstract information on age, gender, date of diagnosis, socio-
economic status (SES), white cell count (WCC), cytogenetics, co-mor-
bidity [4], distance from hospital (in miles), type of non-IC, or reasons
for not receiving therapy, haematological improvement (HI, defined by
transfusion-independence, absolute neutrophil count of ≥1 and un-
supported platelet count ≥50) and date of death or last follow-up. The
patient’s residence postcode was used to infer SES, using the Scottish
Index of Multiple Deprivation (SIMD) tool (https://www2.gov.scot/
Topics/Statistics/SIMD) [5]. SIMD, a relative measure of deprivation,
uses 7 domains (income, employment, education, health, access to
services, crime and housing) to numerically rank different geographical
areas. Indices were assigned to decile categorical indicators for SES,
ranging from SES1 (lowest) to SES10 (highest).
2.2. End-points and statistical analysis
Determinants of treatment and overall survival (OS) were the study
end-points. OS from the date of diagnosis to death or last follow‐up was
analysed using the log‐rank test for Kaplan Meier survival. Co-variates
potentially affecting treatment-decisions or OS (age, SES, co-morbidity,
year of diagnosis, hospital-distance and WCC) were treated as con-
tinuous variables and analysed using the ANOVA or Mann-Whitney U.
test Gender, karyotype (adverse or standard), non-IC and HI were
considered as categorical co-variates for analysis using the Chi-Squared
(χ2) or Fisher’s exact test (https://www.r-project.org/). All P‐values
were two‐tailed and statistical significance was set at the level of
P<0·05.
3. Results
3.1. Patient demographics and treatment determinants
Between 2001 and 2018, of 230 patients with an im-
munophenotypic diagnosis of AML, 121 were considered unsuitable for
intensive chemotherapy and potentially eligible for non-IC. One patient
who received azacitidine was excluded; of the remaining 120 patients
(median age 77 years, range 44–91, 76 males and 44 females), 28 (23
%) received low-dose cyatarbine (40 mg per day subcutaneously for 10
days at intervals of 4–6 weeks) as a single agent, or in combination with
other agents. Of the 92 patients managed exclusively with SC, reasons
for not administering non-IC had been documented in 70 patients and
included patient refusal (n = 10), perceived frailty (n = 30), including
cognitive impairment (n = 2) and concurrent malignancy (n = 3),
death before discussions (n = 3), secondary AML (n = 7) or adverse
karyotype (n = 31). Multiple factors influenced the decision to not
offer non-IC in 10 patients. The likelihood of receiving non-IC reduced
with increasing co-morbidity (ANOVA F = 6.4, p = 0.013), adverse
karyotype (χ2 = 13, p< 0.001) and lower SES (ANOVA F = 4.1, p =
0.044) (Table 1). In total, 28 patients received non-IC (median 3 cycles,
range 1–11).
3.2. Early mortality and disease response
Of 120 patients, 37 (31 %) died within 30 days of diagnosis; 18 (15
%) had survived for ≤10 days. In patients receiving non-IC, the 30-day
mortality was lower (10 %) and comparable to clinical trials of non-IC
that predominantly include [6] or restrict entry to patients with a
performance status (PS) of ≤2 [7]. Disease response (HI) was observed
in 5 (18 %) patients receiving non-IC.
3.3. Survival and determinants
The median survival for the entire cohort was 55 days (95 %CI
37–73), with survival in those receiving non-IC being superior (117
days, 95 %CI 70–164) to SC (46 days, 95 %CI 29–63, p = 0.031)
(Fig. 1A). By univariate analysis, increasing age (HR 1.03 95 % CI
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1.00–1.05, p = 0.045) and WCC (HR 1.01, 95 % CI 1.0–1.02, p =
0.000) associated with poorer survival. Survival improved with non-IC
(HR 0.62, 95 % CI 0.40-0.96, p = 0.031) and HI (HR 0.36, 95 % CI
0.13-0.98, p = 0.045, n = 5). A favourable trend was also observed
with higher SES (HR 0.94, 95 % CI 0.88–1.01, p = 0.074) and its as-
sociated variable, longer hospital-distance (HR 0.98, 95 %CI 0.97–1.0,
p = 0.069) (p = 0.013, Pearson’s correlation). No significant re-
lationships between SES and WCC, or WCC and non-IC were identified.
When the survival of non-IC-treated patients without HI (non-re-
sponders, n = 23) was compared to SC (n = 92), the negative impact of
a high WCC (HR 1.01, 95 % CI 1.00–1.02, p = 0.000) and benefits of
higher SES (HR 0.91 95 % CI 0.85-0.98, p = 0.01) and longer hospital-
distance (HR 0.98 95 %CI 0.97–1.00, p = 0.058) persisted but the OS
benefit with non-IC was lost (HR 0.72, 95 % CI 0.45–1.15, p = 0.17)
(Fig. 1B). In landmark analysis, a higher proportion of non-responders
was alive at 90 days than SC (HR 2.13 95 %CI 1.09–4.15, p = 0.027)
(Fig. 1B). No survival difference was observed at 180 days.
In analysis adjusted for hospital-distance, WCC and non-IC, SES was
the only co-variate associating with survival (HR 0.91, 95 % CI 0.84-
0.98, p = 0.015) for the entire cohort and non-responders (HR 0.89, 95
% CI 0.82-0.97, p = 0.005) including at 90 days (HR 0.90, 95 % CI
0.82-0.99, p = 0.028). The association between improved survival and
SES has been suggested in a UK-based General Practice dataset, al-
though patients were not stratified by treatment-intensity [8].
4. Discussion
Based on our experience in a single-payer health system,< 50 % of
AML patients unsuitable for intensive chemotherapy will be candidates
for novel non-IC. This figure could be lower, as our methodology for
identifying AML patients may have excluded untreated patients in
whom immunophenotyping was not undertaken to confirm AML. Since
our patient cohort consisted exclusively of those treated with low-dose
cytarabine, target numbers for non-IC could increase with the avail-
ability of more potent anti-leukemic drugs, particularly in disease with
poor-risk genetic features. However, non-biological factors [9] in-
cluding SES and immortal time bias (often unrepresented in clinical
trials) are likely to remain important determinants of treatment. To
optimize up-take of non-IC, the reasons for lower SES patients being less
likely to receive treatment require study, and using objective measures
of frailty should aid unbiased decision-making.
Amongst determinants of survival, the negative impact of socio-
economic deprivation independent of non-IC and HI, was of particular
interest in the absence of a correlation between SES and co-morbidity.
Plausible biological reasons include greater frailty in patients from
lower SES or differences in the delivery of supportive care including
anti-microbial prophylaxis, but non-biological factors such as lower
levels of motivation, compliance and/or early engagement with
healthcare professionals too may contribute to inferior survival in those
with lower SES, as suggested in the setting of intensive chemotherapy
[10].
While advances in non-IC will improve outcomes in a proportion of
AML patients, and broadening eligibility criteria in clinical trials may
make the results more realistic, a holistic approach aiming to under-
stand and improve patient perceptions and experience, particularly in
relation to SES is essential to reduce unconscious bias and offer equi-
table healthcare.
Table 1
Variables influencing non-intensive therapy (non-IC).
Covariate Total No.
(%)
No. receiving non-IC
(%)
p
Age 0.13
Median (range) 77 (44–91)
≤70 years 34 (28) 8 (24)
> 70 years 86 (72) 20 (23)
Gender 0.82
Male 76 17 (22)
Female 44 10 (23)
SES (decile) 0.044
Median (range) 7 (1–10)
1-3 28 (23) 9 (32)
4–6 31 (26) 11 (35)
7-10 61 (51) 8 (13)
Year of diagnosis 0.56
≤2007 53 (44) 11 (21)
> 2007 67 (56) 17 (23)
White cell count (x 109/L)* 0.24
Median (range) 9 (0.6-303)
≤10 60 (52) 16 (27)
10-50 29 (25) 4 (14)
≥50 26 (23) 8 (31)
Cytogenetics* 0.001
Adverse 31 (26) 0 (0)
Standard 87 (74) 28 (32)
Charlson co-morbidity score* 0.013
Median (range) 6 (3–12)
< 5 16 (14) 3 (19)
≥5 99 (86) 24 (24)
Hospital-distance 0.68
Median (range) 7.5 (1–51)
< 5 miles 45 (38) 11 (24)
5–10 miles 24 (20) 5 (21)
> 10 miles 51 (41) 12 (24)
Non-IC
Yes 28 (23)
No 92 (77)
* data not available for all patients.
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Fig. 1. Overall survival (OS) of AML patients unsuitable for intensive chemotherapy. Patients receiving non-IC had a superior survival compared to those receiving
Supportive Care (A). Despite absence of HI, more patients receiving non-IC were alive at 90 days than those on Supportive Care (B).
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